Oxybutynin
- Generic Name
- Oxybutynin
- Brand Names
- Ditropan, Gelnique, Kentera, Oxytrol, Kentera (previously Oxybutynin Nicobrand)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO3
- CAS Number
- 5633-20-5
- Unique Ingredient Identifier
- K9P6MC7092
- Background
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.
...
- Indication
Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a...
- Associated Conditions
- Bladder Spasms, Detrusor Hyperreflexia, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
- Conditions
- Interventions
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 50
- Registration Number
- NCT06737016
- Locations
- 🇪🇬
Mansoura Urology and Nephrology Center, Mansoura, Dakahlia, Egypt
REDucing Hot FLASHes in Women Using Endocrine Therapy.
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Reinier de Graaf Groep
- Target Recruit Count
- 260
- Registration Number
- NCT06106529
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT05550246
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 126
- Registration Number
- NCT05100017
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT04600336
- Locations
- 🇺🇸
McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, United States
🇺🇸Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
🇺🇸Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States
A Novel Pharmacological Therapy for Obstructive Sleep Apnea
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT03919955
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy of Oxybutynin in Paediatric Cystitis
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 81
- Registration Number
- NCT03877289
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.